140 related articles for article (PubMed ID: 25792627)
21. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.
Zaidi M; Epstein S; Friend K
Ann N Y Acad Sci; 2006 Apr; 1068():560-3. PubMed ID: 16831952
[TBL] [Abstract][Full Text] [Related]
22. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
23. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
[TBL] [Abstract][Full Text] [Related]
24. [Clinical study on combination of multiple regimens in treatment of osteoporosis in perimenopause and postmenopausal women].
Guan YT; Cai LL; Ding HX; Chen GD; Hu Y
Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):571-4. PubMed ID: 21029610
[TBL] [Abstract][Full Text] [Related]
25. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women.
Gonnelli S; Caffarelli C; Tanzilli L; Pondrelli C; Lucani B; Franci BM; Nuti R
Bone; 2014 Apr; 61():27-32. PubMed ID: 24389416
[TBL] [Abstract][Full Text] [Related]
26. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
27. Comparing the effect of short term post meals and bedtime calcium supplementation on the C-terminal telopeptide crosslinks and PTH levels in postmenopausal osteopenic women.
Chuengsamarn S; Suwanwalaikorn S
J Med Assoc Thai; 2005 Jun; 88 Suppl 1():S12-20. PubMed ID: 16858933
[TBL] [Abstract][Full Text] [Related]
28. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.
Anagnostis P; Vyzantiadis TA; Charizopoulou M; Adamidou F; Karras S; Goulis DG; Karagiannis A; Garipidou V; Vakalopoulou S
Thromb Haemost; 2013 Aug; 110(2):257-63. PubMed ID: 23740140
[TBL] [Abstract][Full Text] [Related]
29. Oral weekly ibandronate prevents bone loss in postmenopausal women.
Tankó LB; Felsenberg D; Czerwiński E; Burdeska A; Jonkanski I; Hughes C; Christiansen C;
J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
[TBL] [Abstract][Full Text] [Related]
30. Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis.
Schlosser K; Scigalla P
Scand J Clin Lab Invest Suppl; 1997; 227():21-8. PubMed ID: 9127465
[TBL] [Abstract][Full Text] [Related]
31. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
32. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
[TBL] [Abstract][Full Text] [Related]
33. The Relevance of Osteoclastic and Osteoblastic Activity Markers Follow-Up in Patients on Antiresorptive Osteoporosis Treatment.
Smilic TN; Novakovic TR; Markovic-Jovanovic SR; Smilic LLJ; Mitic JS; Radunovic ML
J Clin Densitom; 2018; 21(3):322-328. PubMed ID: 29103946
[TBL] [Abstract][Full Text] [Related]
34. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
35. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Lai PS; Chua SS; Chew YY; Chan SP
J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
[TBL] [Abstract][Full Text] [Related]
36. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
Ravn P; Neugebauer G; Christiansen C
Bone; 2002 Jan; 30(1):320-4. PubMed ID: 11792604
[TBL] [Abstract][Full Text] [Related]
37. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
38. Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.
Schafer AL; Sellmeyer DE; Palermo L; Hietpas J; Eastell R; Shoback DM; Black DM
J Clin Endocrinol Metab; 2012 Oct; 97(10):3522-9. PubMed ID: 22791766
[TBL] [Abstract][Full Text] [Related]
39. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
[TBL] [Abstract][Full Text] [Related]
40. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
